

The banner features a photograph of the South San Francisco Conference Center on the left, with a decorative graphic of colorful, overlapping leaves on the right. The title 'LakePharma Protein Engineering Symposium' is prominently displayed in white text against a dark background.

LakePharma Protein Engineering Symposium

Friday, October 7th, 2016

South San Francisco Conference Center

Agenda

8:30 am	Breakfast and Registration
8:55 am	Welcome Remarks
9:00 – 9:35 am	<ul style="list-style-type: none">• David Johnson, Ph.D., CEO, GigaGen "Recombinant expression of millions-diverse natural antibody repertoires as a replacement for plasma-derived intravenous immunoglobulin"
9:35 – 10:10 am	<ul style="list-style-type: none">• Shelley Force Aldred, Ph.D., VP of Pre-clinical Development, TeneoBio "Winning the numbers game: Developing novel multi-specific therapeutics from a large and diverse collection of human domain antibodies"
10:10 – 10:40 am	Morning Break in Exhibition Area
10:40 – 11:15 am	<ul style="list-style-type: none">• Guy Cavet, Ph.D., Chief Technology Officer, Atreca "Intelligent discovery of antibodies from humans and other animals"
11:15 – 11:50 am	<ul style="list-style-type: none">• Yasmina Abdiche, Ph.D., Research Fellow, Rinat/Pfizer "Advances in the analytical methods used to characterize the epitopes of monoclonal antibodies"
11:50 am – 1:30 pm	Lunch & Breakout Sessions
12:45 – 1:15 pm	<ul style="list-style-type: none">• The Trianni human antibody discovery platform <i>David Meiningner, Ph.D., Chief Business Officer, Trianni</i> <i>John "Lippy" Lippincott, Ph.D., VP of Antibody Discovery, LakePharma</i>• High-capacity system for rapid purification of antibodies using Protein A membranes <i>Keren Drori, Ph.D., Program Manager, Takara</i>• Introduction to the Expi-class transient expression systems, applications and considerations <i>Henry C. Chiou, Ph.D., Associate Director, Cell Biology, Thermo Fisher</i>• Grifols: A legacy in antigen development and engineering <i>Elizabeth Booth, Ph.D, Scientist, Grifols Diagnostic Solutions</i>
	Afternoon Sessions
1:30 -1:40 pm	<ul style="list-style-type: none">• Hua Tu, Ph.D., CEO, LakePharma Brief remarks
1:40 – 2:15 pm	<ul style="list-style-type: none">• Kexin Huang, Ph.D., Director of Antibody Engineering, LakePharma "Bispecific antibody engineering and development at LakePharma"
2:15 – 2:50 pm	<ul style="list-style-type: none">• Jill Carton, Ph.D., Director of R&D, Janssen Biotherapeutics "Multi-specific antibody therapeutics, advancements and lessons learned from discovery to early development"
2:50 – 3:20 pm	Afternoon Break and Poster Sessions
3:20– 3:55 pm	<ul style="list-style-type: none">• Anatoly Shcherbatko, Ph.D., Associate Research Fellow, Rinat/Pfizer "Modulation of P2X3 and P2X2/3 receptors by monoclonal antibodies"
3:55 – 4:30 pm	<ul style="list-style-type: none">• William Robinson, M.D., Associate Professor, Stanford University "Sequencing antibody répertoires to decipher pathogenic mechanisms in rheumatoid arthritis"
4:30 pm	Raffle and Closing Remarks
4:30 – 6:00 pm	Networking & Happy Hour



LakePharma Protein Engineering Symposium

Friday, October 7th, 2016
South San Francisco Conference Center

Speaker Biographies

David Johnson, Ph.D., MBA
CEO, GigaGen

Dr. Johnson is an inventor, entrepreneur, and expert in single-cell genomics with a track record of bringing new medical technologies to market. As Founder and CEO of GigaGen, Dr. Johnson has raised >\$11 million in mostly non-dilutive capital to build patented, world-leading technologies for immune repertoire genomics. GigaGen is now leveraging this technology for internal development of novel therapies for oncology and immunology indications. Previously, Dr. Johnson was among the founding members and COO of Natera (NASDAQ: NTRA). At Natera, Dr. Johnson was responsible for all clinical operations, laboratory research, clinical studies, and clinical product development. Prior to Natera he was the ENCODE Project Director at the Stanford Human Genome Center. Dr. Johnson holds a BS in Biology from Duke University, a PhD in Genetics from Stanford University, and an MBA from the Haas School of Business at the University of California, Berkeley.

Yasmina Abdiche, Ph.D.
Research Fellow, Rinat/Pfizer

Dr Abdiche is a Research Fellow at Rinat, part of Pfizer's Oncology Research Unit, located in South San Francisco, California, in the United States, where she leads a Bioanalytical group that uses label-free biosensors, automation, and mass spectrometry to support core research projects. After graduating from Oxford University in the UK with a Master's degree in Chemistry and a PhD in Biological Chemistry, Dr Abdiche completed post-doctoral research in Dr David Myszka's laboratory at the University of Utah in Salt Lake City, where she optimized biosensor methods for characterizing small molecule interactions and helped to establish carbonic anhydrase as a benchmark model system. Dr Abdiche joined Rinat Neuroscience in 2004 and is co-inventor of several Rinat molecules that are currently in clinical trials, including TEV-48125 (formerly RN307), an anti-CGRP antibody which demonstrated POC in PhIIb clinical trials for migraine, bococizumab, a PCSK9 inhibitor currently in PhIII clinical trials for hypercholesteremia, and PF06801591, an anti-PD-1 antibody which entered PhI clinical trials for cancer immunotherapy in 2016.

Shelley Force Aldred, Ph.D.
Vice President of Pre-clinical Development, TeneoBio

Dr. Force Aldred is currently serving as VP for Pre-clinical Development at TeneoBio. TeneoBio develops next-generation therapies for the treatment of cancer and infectious disease by combining uniquely engineered rat models, next-generation sequencing for antibody repertoire profiling, and high-throughput recombinant expression and screening of antibody leads. Dr. Force Aldred was formerly director of worldwide R&D for Active Motif, which she joined in 2013 when Active Motif acquired SwitchGear Genomics. In 2006, she co-founded SwitchGear Genomics with Richard Myers and Nathan Trinklein, colleagues in the Department of Genetics at Stanford University. Prior to founding SwitchGear Genomics, Shelley was a graduate student then senior scientist on Stanford's ENCODE Project team.

Guy Cavet, Ph.D.
Chief Technology Officer, Atreca

Dr. Cavet is co-founder and Chief Technology Officer of Atreca, which reveals the activity of the adaptive immune system with unprecedented precision. Guy's career interest is the use of novel technologies to advance medicine. Prior to Atreca he led teams in Informatics and Computational Biology at pharmaceutical and diagnostic companies including Nodality, Crescendo Bioscience, Genentech, Merck and Rosetta Inpharmatics. Dr. Cavet has a Bachelor's degree in Biochemistry and a Ph.D. in Molecular Biology from Cambridge University.



LakePharma Protein Engineering Symposium

Friday, October 7th, 2016

South San Francisco Conference Center

Speaker Biographies Cont.

Anatoly Shcherbatko, Ph.D.

Associate Research Fellow, Rinat/Pfizer

Dr. Shcherbatko boasts over 15 years of experiences in the industry, spending the past 12 years as an associate research fellow with Pfizer. Prior to joining Pfizer, Dr. Shcherbatko spent four years at Merck as a senior research biologist. He also was a research assistant professor at SUNY Stony Brook. He has coauthored numerous scientific publications, including publications on modulation of P2X3 and P2X2/3 Receptors by monoclonal antibodies and engineering highly potent and selective microproteins against Nav1.7 Sodium Channel for treatment of pain.

Jill Carton, Ph.D.

Director of R&D, Janssen Biotherapeutics at Janssen

Jill M. Carton, Ph.D. is currently a Director in Janssen Biotherapeutics, Biologics Research. She received a B.S. in Biology from Fairfield University, Connecticut and an M.S. and Ph.D. in Molecular and Cellular Biology from Fordham University, New York. Following graduate school, Jill took a post-doctoral fellowship at Johnson & Johnson, Pharmaceutical Research Institute in Raritan, NJ on the inflammation team. She identified potential inflammatory disease drug targets through differential display and microarray chip technologies. Jill transferred into a Research Scientist position at Centocor, Inc. Malvern, PA. After joining Janssen R&D, Jill took on increasing responsibilities focused on Protein Therapeutic discovery. Jill has worked in Biologics Research with particular interest in early discovery projects through therapeutic project transition from discovery to development. Highlights from Jill's efforts include contributing to the discovery and development of Simponi, direct contribution to the discovery and transition to development of seven monoclonal antibody therapeutics, and the development and implementation of a process for therapeutic coding sequence engineering for improved protein expression in manufacturing cell lines. Currently, Jill is heading the Lead Optimization team for the Oncology and Infectious Diseases portfolio within Janssen BioTherapeutics.

Kexin Huang, Ph.D.

Director of Antibody Engineering, LakePharma

Dr. Huang has served as LakePharma's Director, Antibody Engineering since 2014. She is responsible for building LakePharma's world class antibody engineering team and establishing the engineering platforms for humanization, affinity maturation and other surface display related engineering services. With over ten years of structural biology experience and an in-depth knowledge of biophysical and bioanalytical strategies, she has streamlined the engineering process with her team, and ensures exceptional quality for LakePharma's customers. Dr. Huang earned her B.S. in biochemistry and molecular biology at the Peking University and her Ph.D. in biochemistry (structural biology) at Baylor College of Medicine.

William Robinson, M.D., Ph.D.

Associate Professor of Medicine, Stanford University

Dr. Robinson is a co-founder of Atreca and is currently Associate Professor of Medicine in the Division of Immunology and Rheumatology of the Department of Medicine at Stanford University. At Stanford, he is Director of the Stanford Osteoarthritis Initiative and a co-lead of the Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus Network of the NIH. Dr. Robinson was elected to the American Society of Clinical Investigation (ASCI) and the Henry Kunkel Society. He and his laboratory members invented the technology underlying Atreca's Immune Repertoire Capture™ technology. He is an inventor on twenty-one patent applications, and technologies developed in his Stanford and VA laboratories have been licensed to seven companies in the biotechnology industry. Dr. Robinson was a co-founder of Bayhill Therapeutics. Dr. Robinson received his BS, MD, and PhD degrees from Stanford University and completed his clinical training in internal medicine at the University of California, San Francisco.



LakePharma Protein Engineering Symposium

Friday, October 7th, 2016
South San Francisco Conference Center

Speaker Biographies Cont.

Elizabeth Booth, Ph.D.

Scientist, Grifols Diagnostic Solutions

Dr. Booth is a collaborative research scientist with eight years of experience across multiple biological and engineering disciplines. She has spent the last year-plus as a scientist with Grifols Diagnostic Solutions and prior to that she was a Post Doctoral Researcher at the University of California Berkeley. Dr. Booth received her PhD from Carnegie Mellon University in Chemical Engineering. Dr. Booth has been first author and coauthored numerous scientific publications.

Keren Drori, Ph.D.

Product Manager, Clontech

Dr. Drori has nearly 20 years of research and commercial experience in academia and the life sciences industry. She is a molecular biologist and biochemist by training, having completed her PhD at Tel Aviv University and a post-doctoral research fellowship at Stanford University. Dr. Drori has long been involved in the launch of novel technology platforms and development of innovative products. She currently serves as the Product Manager for Protein Expression and Purification Technologies at Takara Bio USA.

Henry C. Chiou, Ph.D.

Associate Director, Cell Biology, Thermo Fisher

Henry Chiou, Ph.D., is an Associate Director of Product Management, responsible for the Gibco and Invitrogen-branded protein expression portfolio at Thermo Fisher Scientific. Henry has been involved in or directed development of such products as Lipofectamine® LTX, Lipofectamine® RNAiMAX, Lipofectamine® 3000, the FreeStyle™ MAX CHO Expression System, the Expi293™ Expression System and the ExpiCHO system. Henry previously worked for small biotech companies in gene delivery and gene therapy. He received his Ph.D. from Harvard University and did his post-doctoral training at the University of Pennsylvania.

John “Lippy” Lippincott, Ph.D.

VP of Antibody Discovery, LakePharma

Dr. Lippincott has served as LakePharma's Vice President of Antibody Discovery since February 2016. He has over 16 years of experience in drug discovery and is inventor on multiple therapeutic antibody patents representing several molecules that have made it into the clinic. During his work at Pfizer and Igenica Inc., he explored and mastered many novel immunization strategies and techniques in addition to refining and optimizing hybridoma screening techniques. Additionally, from his work at Ablexis LLC, he brings a wealth of experience working with transgenic mice used in the discovery of human antibodies. Dr. Lippincott has B.S. degrees in both microbiology and biochemistry from the University of Washington and obtained his Ph.D. in cell biology at Harvard Medical School.

David Meininger, Ph.D., MBA

Chief Business Officer, Trianni

Dr. Meininger was previously Executive Director, Business Development & Licensing with Merck where he had global responsibility for biologics technologies as a member of the West Coast Innovation Hub. Prior to his transition to business development, he led Protein Science and managed biologic lead generation for immuno-oncology and other programs that progressed to development and onto market. At Amgen, he served on multiple teams that advanced programs from discovery through the clinic. Dr. Meininger completed his postdoc in Protein Engineering at Genentech, received his PhD from UCSD and his MBA from The University of Washington.



LakePharma Protein Engineering Symposium

Friday, October 7th, 2016
South San Francisco Conference Center

Poster Session

2:50 PM – 3:20 PM

High-capacity system for rapid purification of antibodies using Protein A membranes

Keren Drori, Sayantan Mitra, Michael T. Vierra, Tatiana Garachtchenko, Boris Levitan, Gia Jokhadze, and Andrew A. Farmer
Clontech Laboratories, Inc.

Novel Systems for Rapid Purification of Recombinant Proteins and Antibodies on High Capacity Membranes

Gia Jokhadze, Sayantan Mitra, Michael T. Vierra, Boris Levitan, Andrew A. Farmer
Clontech Laboratories, Inc.

Bispecific T-cell Engaging Antibody Targeting AFP/MHC Complex for the Treatment of Liver Cancer

Dr. Jingyi Xiang
Eureka Therapeutics

LakePharma's CHO-GSN Platform

Silka Cheng
LakePharma

Improving and Accelerating AAV production process; Establishing a complete disposable production platform for the production of AAV

Ishita Shah
Adverum Biotechnologies

A Novel T-cell Engaging Bispecific Antibody Platform Developed Using Sequence-based Discovery in Unique Transgenic Rats

Starlynn Clarke, Duy Pham, Shelley Force Aldred, Nathan Trinklein, Ute Schellenberger, Katherine Harris, Kevin Dang, Payal Pratap, Harshad Ugamraj, Marianne Bruggemann, and Wim vanSchooten
TeneoBio

PD-L1 Heavy Chain Antibody Discovery Using Antibody Repertoire Sequencing and High-throughput Recombinant Expression

Katherine Harris, Shelley Force Aldred, Nathan Trinklein, Ute Schellenberger, Starlynn Clarke, Kevin Dang, Duy Pham, Marianne Bruggemann, and Wim vanSchooten
TeneoBio

De Novo Antibody Sequencing Can Identify Multiple Chains in a Mixed Sample

Alice Liang
LakePharma

Exploring the potential of non-natural protein folds to be engineered for synthetic applications

Dr. Gareth Shannon, Dr. Chenyu Wei, Dr. Andrew Pohorille
NASA Ames Research Center



LakePharma Protein Engineering Symposium

Friday, October 7th, 2016
South San Francisco Conference Center

Poster Session, Cont.

2:50 PM – 3:20 PM

UniRat™ – A Discovery Platform for Human Heavy Chain Antibodies with High Affinity and Stability

Harshad Ugamraj, Payal Pratap, Kevin Dang, Kat Harris, Duy Pham, Shelley Force Aldred, Nathan Trinklein, Ute Schellenberger
TeneoBio

Proof that can travel – Documented clonality report for regulatory submission

Paul Miller
Solentim, Inc.

Integrated transcriptomic and proteomic profiling of an antibody repertoire

Anand Patel¹, Katherine Harris², Nathan Trinklein², Natalie Castellana¹, Stefano Bonissone¹
Digital Proteomics LLC, La Jolla, CA¹
TeneoBio Inc., Menlo Park²

Novel recombinant LDV-Fc “carrier” molecules allow for homogenous conjugation at their unique N-terminal amine groups

Gray Shaw
Belmont Biosciences, Inc.

Protein Manufacturing Utilizing a Titerless Baculovirus Platform

Norman Garceau
LakePharma

High Throughput Characterization of Biologics Using Automated Microfluidic Viscometry

Dr. David Nieto Smiavilla, Ivan Akhremitchev, Dr. Seong-Gi Baek
Presenters: Lu Lu & Grace Baek
RheoSense, Inc.

ExpCHO Transient Expression System: Applications and Comparative Data

Henry Chiou
ThermoFisher

AbGenesis: A powerful platform for in vivo immunization monitoring, rapid biomarker discovery, library screening and affinity maturation

Sarah Ives
Distributed Bio

Eliminating Steps in the Bioprocess Pipeline with Aseptic Optimum Growth™

Joe Machamer
Thomson Instrument Company

Massive and high content antibody screening – one cell at a time

Allison Schulkins
Single Cell Technology, Inc.



LakePharma Protein Engineering Symposium

Friday, October 7th, 2016
South San Francisco Conference Center

Online Registration:

Open through Wednesday, October 4, 2016
www.lakepharma.com/symposium

Symposium Organizing Committee:

Norman Garceau, Ph.D., VP of Technology, LakePharma
John "Lippy" Lippincott, Ph.D., VP of Antibody Discovery, LakePharma

Announcement:

Email symposium@lakepharma.com to submit abstracts for poster session (subject to availability)

Symposium Sponsors and Exhibitors:

